On 5 February, IFPMA delivered a statement at the 7th Meeting of the Working Group on Amendments to the International Health Regulations (2005) in Geneva, Switzerland.
Read moreMedical breakthroughs provide hope to patients, families and caregivers all over the world. However, we know that these ground-breaking advances in healthcare are only meaningful when they can reach the people who need them. To be successful, we need to be as innovative in our approaches to patient access as we are in the scientific discovery and development of medicines and vaccines themselves.
Read more
Regulatory agility played a crucial role in speeding up the development and approval of medicines and vaccines during the COVID-19 pandemic. The insights gained from this success are valuable for continually strengthening regulatory frameworks, both in emergency and non-emergency situations. IFPMA collaborated with external researchers to gather insights from national regulatory authorities and pharmaceutical companies on the success factors behind regulatory agility, especially ahead of future pandemics.
Read more
This report aims to explore the perspective of members of NRAs on the use of regulatory agilities which emerged during the COVID-19 pandemic and describe lessons learnt from this experience.
Read more
On 24 January, IFPMA delivered a statement on antimicrobial resistance (AMR) at the WHO 154th Executive Board in Geneva, Switzerland.
Read moreOn 25 January, IFPMA delivered a statement on health emergencies at the WHO 154th Executive Board in Geneva, Switzerland.
Read moreOn 24 January, IFPMA, GSCF, and IGBA delivered a joint constituency statement on non-communicable diseases and Universal Health Coverage (UHC) at the WHO 154th Executive Board in Geneva, Switzerland.
Read moreEncouraging clinical research in low-income settings is essential to tap into opportunities that can make a difference in patients’ lives. Sarah Adam, Associate Director, Regulatory Affairs at IFPMA, shares perspectives on key pillars to support this.
Read more
In September, some 200 Heads of State and top political decision-makers met in New York for the annual United Nations General Assembly. They recommitted to the UN Sustainable Development Goals (SDGs), with a political declaration pledging to “act with urgency to realize the [Agenda 2030]Â vision.” Halfway to 2030 and with the clock ticking, the renewal...
Read more
On 7 December, IFPMA submitted a statement to the 6th Meeting of the Working Group on Amendments to the International Health Regulations (2005), happening in Geneva, Switzerland.
Read moreIn view of a growing complexity of product lifecycle management, industry puts forward perspectives to support the harmonization of regulatory requirements. These are intended to facilitate efficient regulatory review and approval to support timely implementation of changes and product improvements, leading to more resilient supply chains.
Read more
On 3 December, innovative pharmaceutical trade associations issued a joint statement on the Declaration on Climate and Health at COP28.
Read more